Marijuana May Not be the Right Alternative Pain Remedy
Many patients who are being treated for opioid addiction in a medication-assisted treatment clinic use marijuana to help manage their pain and mood symptoms.
But new research led by Marian Wilson, Ph.D., of the Washington State University College of Nursing found that frequent marijuana use seems to strengthen the relationship between pain and depression and anxiety, not ease it.
“For people who are using cannabis the most, they have a very strong relationship between pain and mood symptoms, and that’s not necessarily the pattern you’d want to see,” Wilson said. “You would hope, if cannabis is helpful, the more they use it the fewer symptoms they’d see.
The research, recently published in the journal Addictive Behaviors, involved 150 patients being seen at an opioid treatment clinic. Previous studies have shown that nearly two-thirds of patients receiving medication-assisted treatment for opioid addiction also have chronic pain, and many experience depression and anxiety.
About 67 percent of the clinic patients surveyed by Wilson and her team said they had used marijuana in the past month.
Research by Wilson, WSU College of Nursing, shows that frequent marijuana use seems to strengthen the relationship between pain and depression and anxiety.
“Some are admitting they use it just for recreation purposes, but a large number are saying they use it to help with pain, sleep, and their mood,” Wilson said. “We don’t have evidence with this study that cannabis is helping with those issues.” In fact, the relationship between pain and depression and anxiety increased with the frequency of marijuana use.
In most cases, people reported they were self-medicating with marijuana, Wilson noted, yet only a small number had a medical marijuana card.
The study noted that opioid overdose rates have more than tripled in the past two decades and are now the second-leading cause of accidental death in the United States. There are many questions about the relationship between marijuana use and opioid addiction and treatment – such as why opioid death rates are 25 percent lower in states that have legalized medical marijuana – but the primary purpose of Wilson’s study was to see whether cannabis use affects the relationship between pain and depression and anxiety.
Patients believe using marijuana helps them with their symptoms, but the study’s results could indicate the opposite is true for those in addiction treatment – that by strengthening the connection between feelings of pain and emotional distress, it makes it harder for them to manage their symptoms.
“The effectiveness of cannabis for relieving distressing symptoms remains mixed and requires further research,” the study concludes.
This article has been republished from materials provided by Washington State University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Wilson, M., Gogulski, H. Y., Cuttler, C., Bigand, T. L., Oluwoye, O., Barbosa-Leiker, C., & Roberts, M. A. (2018). Cannabis use moderates the relationship between pain and negative affect in adults with opioid use disorder. Addictive Behaviors, 77, 225-231.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
New Microscope Captures Detailed 3-D Movies of Cells Deep Within Living SystemsNews
Merging lattice light sheet microscopy with adaptive optics reveals the most detailed picture yet of subcellular dynamics in multicellular organisms.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.